WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets

Series A

NeuroGyn closes a CHF 4M Series A for a pelvic nerve stimulation implant

MedDevice Startups Staff · Oct 13 · 2 min read · Via NeuroGyn announcement

NeuroGyn said on October 13 that it closed a CHF 4M Series A. A Swiss institutional investor active in medical technology led the round, with private investors alongside, and the company named neither. Proceeds go to starting human clinical studies, regulatory development and the path toward commercialization.

PosStim is built around genital nerve stimulation, a minimally invasive approach to pelvic neuromodulation from Marc Possover, the pelvic nerve surgeon who founded the Zug company. Overactive bladder is the first target, and the release names pelvic pain and male erectile dysfunction as later applications that would each need their own clinical evaluation. The platform is investigational, is not approved and is not for sale. CHF 4M buys a first in human study rather than a registrational one, so another round should come before any submission.

Questions & Answers

How much did NeuroGyn raise in its Series A?

NeuroGyn AG said on October 13, 2026 that it closed a CHF 4 million Series A. A Swiss institutional investor active in medical technology led the round, with private investors alongside, and neither was named.

What is the NeuroGyn PosStim platform?

PosStim is a minimally invasive pelvic neuromodulation platform built around genital nerve stimulation. Overactive bladder is the first clinical target. NeuroGyn says the platform is investigational, is not approved and is not available for sale.

What will NeuroGyn do with the Series A money?

NeuroGyn says the CHF 4 million will fund the start of human clinical studies, regulatory development and work toward commercializing PosStim, including evidence on safety and clinical performance.

← Back to Fundraising